Aug. 12 at 5:40 PM
$PHIO Investor Relations has not gotten back to me about whether they are considering NIH or NCI grant money for a Phase 2. A grant helps this stock price a lot, and permanently. It also cuts the timeline on numerous avenues for this stock, in some cases by years. It also put PHIO on better ground negotiating partnerships.
Depending on the criteria used for the planned Phase 2b-3, I don't think the Complete Response Rate or the Overall Response Rate suffers very much, maybe a low single digit percent decline.
I suppose we are now waiting for an indication that cohort 5 has been fully enrolled, followed by the no adverse events for cohort 5 announcement. No adverse events at max dose obviously would be incredibly bullish and may actually get reflected in the stock price.
The missing cohort 4 member may end up being included in the cohort 5 data announcement.
May start trading PHIO here, it is undervalued at least medium term- short term and long term not sure yet.
